Identifying cytomegalovirus complications using the quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation

Journal of Infectious Diseases

Volumn 215, Issue 11, 2017, Pages 1684-1694

  Yong, Michelle K ^a,b   Cameron, Paul U ^a,b   Slavin, Monica ^b,c,d   Morrissey, C Orla ^a   Bergin, Krystal ^a   Spencer, Andrew ^a   Ritchie, David ^b,c   Cheng, Allen C ^a   Samri, Assia ^e,f   Carcelain, Guislaine ^e,f   Autran, Brigitte ^e,f   Lewin, Sharon R ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e INSERM   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cytomegalovirus; Immunocompromised host; Stem cell transplantation; T cell immunity; Viral immunity

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR; VIRUS DNA;

ADULT; AGED; ALL CAUSE MORTALITY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; INTERFERON PRODUCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VIRAL CLEARANCE; VIREMIA; VIRUS REACTIVATION; ADOLESCENT; ADVERSE EFFECTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INTERFERON GAMMA RELEASE ASSAY; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PROCEDURES; T LYMPHOCYTE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85029668233     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix192     Document Type: Article

References (41)

1. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101:407-14.
2. George B, Pati N, Gilroy N, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010; 12:322-9.
3. Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: A retrospective cohort study. Lancet Haematol 2016; 3:e119-27.
4. Navarro D, Amat P, de la Camara R, et al. Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients. Open Forum Infect Dis 2016; 3:ofw107.
5. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118:173-8.
6. Marty FM, Ljungman P, Papanicolaou GA, et al.; Maribavir 1263-300 Clinical Study Group. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: A phase 3, double-blind, placebo- controlled, randomised trial. Lancet Infect Dis 2011; 11:284-92.
7. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: A global perspective. Preface. Bone Marrow Transplant 2009; 44:453-5.
8. Durand CM, Marr KA, Arnold CA, et al. Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients. Clin Infect Dis 2013; 57:1550-9.
9. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118:179-84.
10. Venton G, Crocchiolo R, Furst S, et al. Risk factors of ganciclovir-related neutropenia after allogeneic stem cell transplantation: A retrospective monocentre study on 547 patients. Clin Microbiol Infect 2014; 20:160-6.
11. Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program 2011; 2011:305-9.
12. Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirusspecific cell-mediated immunity after organ transplant: A primer for the clinician. Clin Infect Dis 2012; 55:1678-89.
13. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLArestricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83:1971-9.
14. Ganepola S, Gentilini C, Hilbers U, et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39:293-9.
15. Abu-Khader A, Krause S. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation-a comparison of different assays for the detection of cytomegalovirus-specific T cells. Eur J Haematol 2013; 91:534-45.
16. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34:1094-7.
17. Walker S, Fazou C, Crough T, et al. Ex vivo monitoring of human cytomegalovirus- specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 2007; 9:165-70.
18. Sacre K, Nguyen S, Deback C, et al. Expansion of human cytomegalovirus (HCMV) immediate-early 1-specific CD8+ T cells and control of HCMV replication after allogeneic stem cell transplantation. J Virol 2008; 82:10143-52.
19. Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, Vittecoq D, et al. Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med 2005 June 20; 201(12):1999-2010.
20. Le Corre N, Thibault F, Pouteil Noble C, et al. Effect of two injections of nonadjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial. Vaccine 2012; 30:7522-8.
21. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of postcytometric complex multivariate datasets. Cytometry A 2011; 79:167-74.
22. Tey SK, Kennedy GA, Cromer D, et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One 2013; 8:e74744.
23. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78:1373-80.
24. Fleming T, Dunne J, Crowley B. Ex vivo monitoring of human cytomegalovirus- specific CD8(+) T-cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J Med Virol 2010; 82:433-40.
25. Bono P, Orlandi A, Zoccoli A, et al. Quantiferon CMV assay in allogenic stem cell transplant patients. J Clin Virol 2016; 79:10-1.
26. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9:1214-22.
27. Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant 2008; 8:1749-54.
28. Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in highrisk solid-organ transplant recipients: A multicenter cohort study. Clin Infect Dis 2013; 56:817-24.
29. Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012; 93:195-200.
30. Chang JJ, Sirivichayakul S, Avihingsanon A, et al. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol 2009; 83:7649-58.
31. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-58.
32. Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008; 73:975-83.
33. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-9.
34. Krol L, Stuchly J, Hubacek P, et al. Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT. Bone Marrow Transplant 2011; 46:1089-98.
35. Sandberg JK, Fast NM, Nixon DF. Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. J Immunol 2001; 167:181-7.
36. Clari MA, Munoz-Cobo B, Solano C, et al. Performance of the QuantiFERONcytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients. Clin Vaccine Immunol 2012; 19:791-6.
37. Ljungman P. Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients? J Clin Virol 2006; 35:493-5.
38. Avetisyan G, Aschan J, Hagglund H, Ringden O, Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 2007; 40:865-9.
39. Giulieri S, Manuel O. QuantiFERON-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev Mol Diagn 2011; 11:17-25.
40. Pourgheysari B, Piper KP, McLarnon A, et al. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant 2009; 43:853-61.
41. Gabanti E, Bruno F, Lilleri D, et al. Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients. PLoS One 2014; 9:e106044.